Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Lexaria Bioscience Corp.

Get SEC filing alerts via email and in your feed for Lexaria Bioscience Corp.

LEXX LEXXW

Lexaria Bioscience Corp.

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a biotechnology company specializing in enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH platform. Its technology improves drug delivery for pharmaceuticals, nutraceuticals, and consumer products across markets like diabetes, weight loss, hypertension, and cannabinoids. The company licenses its IP globally, collaborates with industry partners, and focuses on research, development, and patent protection to maintain competitive advantages.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Lexaria Bioscience Corp.

1
1
Lexaria Bioscience Corp. Lexaria Bioscience Reports Revenue Decline and Improved Net Loss for Six Months Ended February 28, 2026

Via official filing (AI summary) | about 2 months ago | 0 comments

2
1
Lexaria Bioscience Corp. Lexaria Bioscience Reports $1.6 Million Net Loss, Sees Asset Growth Amid Strategic Shift

Via official filing (AI summary) | 5 months ago | 0 comments

3
1
Lexaria Bioscience Corp. Lexaria Bioscience Reports Increased Net Loss and Revenue Growth for Fiscal Year Ending August 31, 2025

Via official filing (AI summary) | 6 months ago | 0 comments

4
1
Lexaria Bioscience Corp. Lexaria Bioscience Reports 40% Revenue Increase but Faces $9.2 Million Net Loss

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
Lexaria Bioscience Corp. Lexaria Bioscience Reports Revenue Increase to $183,923 but Significant Net Losses of $2.7M

Via official filing (AI summary) | over 1 year ago | 0 comments